Erytech Pharma Inc.

205 articles about Erytech Pharma Inc.

• ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023

  6/23/2023

  ERYTECH Pharma announced that all resolutions for which the Board of Directors recommended a vote in favor,including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023

• ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma

  6/14/2023

  ERYTECH Pharma, announced that the Lyon Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma.

• ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes

  6/5/2023

  ERYTECH Pharma announced that Akkadian Partners has initiated legal proceedings to obtain the postponement of the vote on the merger with Pherecydes at the Annual General Meeting on June 23.

• ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023

  5/24/2023

  ERYTECH Pharma announced the availability of the documents for its Annual General Meeting to be held on Friday, June 23, 2023.

• ERYTECH Provides Update on the Announced Combination with PHERECYDES

  5/15/2023

  ERYTECH Pharma,aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided anupdateon the announced combination with PHERECYDES.

• ERYTECH Provides Business and Financial Update for the First Quarter of 2023

  5/9/2023

  ERYTECH Pharma,aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business and financial updatefor thefirst quarter of 2023.

• ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market

  4/17/2023

  ERYTECH Pharma dated April 12, 2023, to transfer the listing of its American Depositary Shares representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market.

• ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022

  3/22/2023

  ERYTECH Pharma (Nasdaq & Euronext: ERYP) today provided a business and financial update for the fourth quarter and full year of 2022.

• ERYTECH Provides Business and Financial Update for the Third Quarter of 2022

  11/21/2022

  ERYTECH Pharma (Nasdaq & Euronext: ERYP),aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial updatefor the third quarter of2022.

• ERYTECH Announces Receipt of Nasdaq Notice - October 13, 2022

  10/13/2022

  ERYTECH Pharma from The Nasdaq Stock Market LLC dated October 7, 2022, indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5450.

• ERYTECH Provides Business and Financial Update for the First Half of 2022

  9/12/2022

  ERYTECH Pharma,aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business and financial updatefor the first half of2022.

• 

  Erytech Abandons BLA Plans for Leukemia Drug, Citing Competitive Market

  8/25/2022

  Erytech Pharma is abandoning plans to submit a Biologics License Application to the FDA for Graspa in hypersensitive acute lymphoblastic leukemia.

• ERYTECH Provides Regulatory Update

  8/24/2022

  ERYTECH Pharma provided a regulatory update, announcing that it is no longer seeking approval for Graspa® in hypersensitive acute lymphoblastic leukemia following feedback from the U.S. Food and Drug Administration.

• ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022

  5/24/2022

  ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the availability of the documents for its Annual General Meeting to be held on Friday, June 24, 2022.

• ERYTECH to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that its Chief Executive Officer, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference.

• ERYTECH Provides Business and Financial Update for the First Quarter of 2022

  5/12/2022

  ERYTECH Pharma,a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business and financial update at the end of March 2022.

• ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar

  4/28/2022

  ERYTECH Pharma announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the “Autorité des Marchés Financiers” and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S.

• ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent

  4/25/2022

  ERYTECH Pharma announced the sale of its U.S. manufacturing facility toCatalent, a leading contract development and manufacturing organization in advanced therapies.

• ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology

  4/6/2022

  ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announces the results from the NOPHO sponsored Phase 2 trial of eryaspase in ALL patients are now published in the British Journal of Haematology.

• ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society

  4/4/2022

  ERYTECH Pharma announced the presentation of its novel red blood cell vesiculation technology at the 24th Meeting of the European Red Cell Society, taking place from April 7 to 11, 2022 in Gazzada Schianno, Italy.